Psyched: Atai’s $214M IPO, MindMed CEO Resigns, Field Trip Applies To Nasdaq, Cybin And Novamind Target Frontline Health Workers
Atai Launches $214 Million Nasdaq IPO Offering
Psychedelics biotech platform Atai life Sciences has announced an initial public offering of approximately 14 million of its common shares, ahead of the company’s expected Nasdaq listing.
